# Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/nivolumab-with-carboplatin-paclitaxel-and-bevacizumab-for-first-line-treatment/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Shunichi Sugawara,J.-S. Lee,Jin‐Hyoung Kang,Hye Ryun Kim,Naoki Inui,Toyoaki Hida,K.H. Lee,Takamasa Yoshida,Hiroshi Tanaka,Cheng‐Ta Yang,Makoto Nishio,Yuichiro Ohe,Tomohide Tamura,Nobuyuki Yamamoto,Chong‐Jen Yu,Hiroaki Akamatsu,Yoshinobu Namba,Naoki Sumiyoshi,Kazuhiko Nakagawa |
| Citations | 202 |
| DOI | 10.1016/j.annonc.2021.06.004 |
| Fields | Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://doi.org/10.1016/j.annonc.2021.06.004 |
| OpenAlex ID | https://openalex.org/W3167668640 |
| PMID | 34139272 |
| Type | article |
| Year | 2021 |

## Paper authors

- [Nobuyuki Yamamoto](https://scholariq.org/researchers/nobuyuki-yamamoto/)
- [Hiroaki Akamatsu](https://scholariq.org/researchers/hiroaki-akamatsu/)
- [Chong‐Jen Yu](https://scholariq.org/researchers/chong-jen-yu/)

## Paper journal

- [Annals of Oncology](https://scholariq.org/journals/annals-of-oncology/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.